Thank you to Dr. Nestor, Dr. Molyneaux, Dr. Yu, and the other notable authors for this exciting publication showing the safety and preliminary efficacy in human patients of this exciting new compound for focal fat reduction. At Sagesse we are excited about the next steps to come! Sagesse Bio Jon Meneese Frederick Beddingfield MD, PhD Humberto C. Antunes Ethan Rigel Chidi Nwankpa, MD, MBA Michael Molyneaux Mark S. Nestor, M.D., Ph.D.
Sagesse Bio
Biotechnology Research
Delivering innovative and life changing therapies to patients with an initial emphasis on focal fat destruction.”
About us
Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications. Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine.
- Website
-
www.sagessebio.com
External link for Sagesse Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2024
Employees at Sagesse Bio
Updates
-
Jon Meneese, CEO of Sagesse Bio, will be speaking during the entrepreneurial showcase at this year's Dermatology Summit. If you are going to be at the JP Morgan conference and have an interest in innovation in the Dermatology space then this is a can't miss!
Our Entrepreneurial Company Showcases at the Annual Dermatology Summit are unique sessions that highlight privately held and small-cap public companies advancing innovative products to improve skin health. Whether you’re an investor on the hunt for the next big thing, a pharma executive exploring partnership opportunities, or a smaller company leader seeking to better understand the entrepreneurial landscape, our showcases offer an exclusive look at how these emerging companies are contributing innovative solutions to the dermatology industry. Read more to see our overview of 2025 Entrepreneurial Showcases: UNION therapeutics A/S, Alpenglow Biosciences, Sagesse Bio, Melanyze, Concerto Biosciences, Clexio Biosciences, and Rubedo Life Sciences. Still haven’t registered? Click the link here -> https://lnkd.in/gkjuR8mg #DermSummit2025 #AdvancingDerm #Dermatology #BioTech #StartUp
-
Sagesse Bio is extremely excited to partner with industry leaders to advance SGY-101, a novel siRNA therapeutic for focal fat reduction and tissue remodeling, into clinical trials https://lnkd.in/gbqWwiJc
Sagesse Bio Accelerates Development of SGY-101 into clinical development for Targeted Fat Reduction in Aesthetic Medicine and Medical Dermatology
accesswire.com
-
Sagesse Bio is excited to leverage Gore Range Capital's skin health expertise and SIRNAOMICS advanced RNAi technology to develop innovative therapeutic solutions for fat reduction in dermatology and aesthetic medicine. https://lnkd.in/gKTrtA_a
-
Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications. Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine.